RE:biorunWe don't know any details of the Abbvie deal besides the upfront of USD 500K and a general remark from Howard that the deal should make Sirona profitable.
So I would be very careful to call out the deal as a failure before we actually have the information.
R+F have a reputation of acting business predators, but I think Sirona just wanted street cred.
The big mistake they made years ago was go to the market without a proper clinical study and that still affects the company in terms of weakness, wasted time and dilution.
I think they are on the right track now.